A case report suggests high doses of oxycodone in breastfeeding mothers can lead to apnea and bradycardia in newborns due to immature metabolic pathways.1


RT’s Three Key Takeaways:

  1. Neonatal Vulnerability: Newborns are highly susceptible to opioid toxicity due to immature hepatic metabolism and renal clearance, which can prolong drug elimination and enhance central nervous system effects.1
  2. Dose-Related Risks: High maternal oxycodone doses exceeding 40 mg per day may result in clinically significant neonatal exposure and cardiorespiratory events via breast milk.1
  3. Clinical Monitoring: Healthcare providers should closely monitor breastfed neonates for signs of respiratory depression and bradycardia when mothers are prescribed opioids for postoperative pain management.1


A term male neonate experienced recurrent episodes of bradycardia, desaturation, and apnea temporally linked to maternal oxycodone use during breastfeeding, according to a case report published by Cureus.1

The infant, born at 37 weeks and four days via repeat cesarean section, was initially admitted to the neonatal intensive care unit (NICU) for transient tachypnea of the newborn (TTN).1 While the initial respiratory distress resolved by day of life two, the infant experienced acute cardiorespiratory events on days three and four after the mother began taking 60 mg per day of oxycodone for postoperative pain.1

“This report highlights the importance of careful monitoring for respiratory depression and bradycardia in neonates exposed to maternal opioids through breast milk, particularly at doses exceeding recommended levels,” said Madison L Wallace and Renee Himmelbaum, the study authors.1

Neonates are particularly vulnerable to opioid toxicity because immature hepatic metabolism and renal clearance can prolong drug elimination, the authors wrote.1 Oxycodone is metabolized into active compounds like oxymorphone, which has a significantly higher affinity for $\mu$-opioid receptors and greater potency than the parent drug.1

The authors noted that the milk-to-plasma ratio of oxycodone often exceeds 3.0, with modeled neonatal exposures reaching up to 10% of a therapeutic infant dose in some scenarios.1 Current clinical guidelines from the King Edward Memorial Hospital (KEMH) recommend maternal doses not exceed 40 mg per day for longer than three days.1 Additionally, the Drugs and Lactation Database (LactMed) suggests limiting maternal use to 60 mg per day for no more than two to three days in infants under two months old.1

During the episodes on days three and four, the neonate’s oxygen saturation dropped as low as 34% and 57%, respectively. The events resolved after the infant was transitioned to donor milk and formula.1 The mother reintroduced breast milk into the infant’s diet 48 hours after her last dose of oxycodone, and the neonate tolerated the feeds without further respiratory distress or illness during a follow-up check.1

The Society for Obstetric Anesthesia and Perinatology (SOAP) acknowledges the risks of neonatal sedation but recommends that oxycodone be used as rescue therapy at the lowest effective dose for the shortest possible duration rather than completely discontinuing the medication due to the drawbacks of alternative opioids.1

“While TTN explains the initial respiratory distress, the subsequent apnea events, particularly on DOL [day of life] four, raise concern for opioid-related central respiratory depression,” the authors said.1


Reference

  1. Wallace M L, Himmelbaum R (March 26, 2026) Neonatal Respiratory Depression Associated With Maternal Oxycodone Use During Breastfeeding. Cureus 18(3): e105882. doi:10.7759/cureus.105882